> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Iovance's October Investor Deck Repeats Its Raised 2026 Revenue Target Of $410 Million–$420 Million
- URL: https://www.bullished.co/iovance-lifts-2026-revenue-target-to-410-million-420-million-in-october-investor-deck-4d79c13a/
- Published: 2026-10-05T21:21:00.000Z
- Updated: 2026-10-06T11:42:57.000Z
- Description: The cell therapy company's refreshed presentation also cites about $304 million in cash and a runway into the second half of 2028.
- Author: Matteo Parrino
- Tags: SEC Filings, IOVA, Industry: Healthcare

[Iovance Biotherapeutics](https://www.bullished.co/tag/iova/)' updated corporate presentation, attached to an [8-K filed Monday](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926113763/tm2627047d1%5F8k.htm?ref=bullished.co), repeats its 2026 revenue guidance of [$410 million to $420 million](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926113763/tm2627047d1%5Fex99-1.htm?ref=bullished.co). The company [raised the range on September 29](https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/tm2626507d1%5Fex99-1.htm?ref=bullished.co) from a prior $350 million to $370 million; the new midpoint is $55 million, or about 15%, above the old one.

## What the filing and deck say

The 8-K, signed by Interim CEO and President Frederick G. Vogt, says Iovance updated the deck it uses at healthcare conferences and with analysts and current stockholders. It is attached as Exhibit 99.1.

Second-quarter revenue was about $99 million, more than 10% above the company's own guidance for the quarter, the [presentation](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926113763/tm2627047d1%5Fex99-1.htm?ref=bullished.co) says. It also cites roughly 66% year-over-year revenue growth in the quarter.

Cash, cash equivalents, short-term investments and restricted cash came to about $304 million as of June 30, 2026\. The company says that supports a runway into the second half of 2028.

Gross margin from cost of sales, excluding depreciation and amortization, was about 56% in the second quarter and 50% year to date.

## The pitch behind the numbers

Iovance describes itself as a pioneer in one-time cell therapy for solid tumors, built on tumor-infiltrating lymphocyte (TIL) treatment. Amtagvi is approved in the U.S., Canada and Australia, and the deck lists about 100 treatment centers as of October 5 and about 2,000 patients treated with commercial and clinical products.

Growth beyond melanoma rests on label expansion. Lifileucel has an FDA fast track designation in lung cancer, with a potential launch in the second half of 2027\. The deck puts the global lung cancer commercial opportunity at roughly seven times its current melanoma opportunity.

In soft tissue sarcoma, a registrational trial began in the second quarter of 2026.

## Market reaction and next dates

Shares closed Monday at $14.15 and traded at $14.11 in Monday after-hours trading, down 0.28% (market data).

The deck's regulatory chart lists the U.K. for the second half of 2026 and Switzerland for the first half of 2027 for Amtagvi. The deck also carries the usual caution that guidance assumes no material change in manufacturing, payor coverage or revenue recognition.

The next marked dates are the U.K. regulatory milestone in the second half of 2026 and Switzerland in the first half of 2027.

*Correction, October 6, 2026: An earlier version of this story said Iovance raised its 2026 revenue guidance in its October investor presentation. The company raised the range on September 29; the presentation repeats it.*

### Sources

- [8-K Filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926113763/tm2627047d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2627047d1\_ex99-1.htm — IOVANCE BIOTHERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001425205/000110465926113763/tm2627047d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR

### More on Iovance Biotherapeutics

- [Iovance Raises Full-Year Revenue Guidance By $55 Million, Citing Record Amtagvi Demand](https://www.bullished.co/iovance-raises-full-year-revenue-guidance-by-55-million-citing-record-amtagvi-demand-bfd63f8d/)

[All Iovance Biotherapeutics (IOVA) coverage →](https://www.bullished.co/tag/iova/)